Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience

Venetoclax (VEN) has been shown to play a synergistic effect in combination with hypomethylating agents (HMAs) in the frontline treatment of acute myeloid leukemia (AML). However, the potential role of this therapy in the relapsed/refractory (R/R) AML setting, still needs to be further unveiled. The...

Full description

Bibliographic Details
Main Authors: Francesco Angotzi, Federica Lessi, Matteo Leoncin, Carla Filì, Mauro Endri, Albana Lico, Andrea Visentin, Stefano Pravato, Anna Candoni, Livio Trentin, Carmela Gurrieri
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Oncology
Subjects:
acute myeloid leukemia
venetoclax
hypomethylating agents
azacitidine
decitabine
relapsed/refractory acute myeloid leukemia
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1370405/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1370405/full

Similar Items